BCG Polysaccharide Nucleic Acid Research Articles

Therapeutic efficacy of chitosan nanoparticles loaded with BCG-polysaccharide nucleic acid and ovalbumin on airway inflammation in asthmatic mice.

In this study, immunoregulation and desensitization therapies were jointly applied in the treatment of asthma, in which chitosan (CS) nanoparticles were used. BALB/c mice were selected and mouse models of asthma were constructed. Mice were divided into 7 groups. A double-chamber plethysmograph, MTT, hematoxylin-eosin staining, and ELISA were used. The expression levels of IL-4 and IL-5 in lung tissue cells were detected. CS-BCG-PSN-OVA sustained-release vaccines significantly alleviated airway hyperresponsiveness (AHR) in asthmatic mice. The numbers of total lymphocytes and eosinophils in BALF were remarkably reduced. The expression levels of IL-4 and IL-5 in lung tissue cells of the treatment groups were dramatically decreased. CS-BCG-PSN-OVA was found in vitro to be able to inhibit OVA-induced T-cell proliferation and upregulate the proportion of CD4+CD25+Foxp3+ T cells. CS-BCG-PSN-OVA sustained-release vaccine could significantly attenuate AHR and airway inflammation in asthmatic mice. Thus, it has a promising application prospect for the treatment of bronchial asthma.

Effects of BCG polysaccharide nucleotides combined with Tripterygium wilfordii polyglycosides on inflammatory factors and T cell subsets in patients with chronic urticaria

Objective To study the effect of BCG polysaccharide nucleic acid combined with Tripterygium wilfordii polyglycoside(TWP) on inflammatory factors and T cell subsets in patients with chronic urticaria. Methods From January 2015 to January 2017, 84 patients of chronic urticaria in Gujiao Central Hospital were selected in the research.The patients were randomly divided into observation group and control group, with 42 cases in each group.The control group was treated with conventional therapy, and the observation group was treated with BCG polysaccharide nucleic acid combined with TWP.The levels of IL-2, IL-4, IL-10, peripheral blood interferon-γ(IFN-γ), T cell subsets(CD4+ , CD8+ , CD4+ /CD8+ ) were observed, and the clinical efficacy was compared. Results After treatment, the total effective rate of the observation group was higher than that of the control group[41(97.62%) vs.36(85.71%)](χ2=3.896, P<0.05). The levels of IL-2 and IFN-γ in the observation group were higher than those in the control group[(314.54±45.47)ng/L vs.(285.04±46.84)ng/L, (310.25±32.80)ng/L vs.(265.14±28.11)ng/L](t=2.928, 6.767, all P<0.05). The levels of IL-4 and IL-10 in the observation group were lower than those in the control group[(18.65±3.14)ng/L vs.(26.09±4.52)ng/L, (57.65±6.34)ng/L vs.(63.74±6.82)ng/L](t=8.760, 4.238, all P<0.05). The levels of CD4+ , CD4+ /CD8+ in the observation group were higher than those in the control group[(39.86±6.96)% vs.(34.44±7.06)%, (1.60±0.14) vs.(1.34±0.15)](t=3.543, 8.212, all P<0.05). The level of CD8+ in the observation group was lower than that in the control group[(24.34±3.99)% vs.(27.24±4.33)%](t=3.191, P<0.05). Conclusion BCG polysaccharide nucleic acid combined with TWP in the treatment of chronic urticaria can effectively increase peripheral blood IFN-γ and IL-2 levels, decrease IL-4, IL-10 levels, improve levels of inflammatory cytokines and T cell subsets(CD4+ , CD8+ and CD4+ /CD8+ ), the efficacy is safe and reliable, it is worthy of application and promotion. Key words: BCG polysaccharide nucleic acid; Tripterygium wilfordii polyglycoside; Drug therapy, combination; Urticaria; Inflammatory factor; Interleukins; Interferon-gamma; T cell subsets

Biological agents in the treatment of chronic urticaria

Chronic urticaria is a common and recurrent allergic disease in dermatology. Antihistamines are the first-line treatment of chronic urticaria, but nearly half of patients show poor responses to antihistamines. Complicated pathogenesis of chronic urticaria, including imbalance of Th1/Th2 cell subsets and abnormality of inflammatory mediators, IgE and anti-FceRⅠ antibody, may be one of the important reasons why chronic urticaria is hard to cure. Biological agents can selectively regulate or inhibit immune abnormality, and have become a new approach to the treatment of chronic urticaria and other urticaria-related skin diseases. Related biological agents mainly include BCG-polysaccharide nucleic acid, gamma globulins, tumor necrosis factor (TNF) -α inhibitors, interleukin (IL) -1 blockers, rituximab, omalizumab, and so on, and play important roles in the treatment of chronic urticaria. Omalizumab, a kind of anti-IgE monoclonal antibody, has a favorable benefit/risk ratio and good tolerability, and is considered to be one of the ideal biological agents for the treatment of chronic urticaria. Key words: Urticaria; Biological agents; Antibodies, monoclonal; Rituximab; Omalizumab

Immunotherapeutic effect of BCG-polysaccharide nucleic acid powder on Mycobacterium tuberculosis-infected mice using microneedle patches

Polysaccharide nucleic acid fractions of bacillus Calmette–Guérin, termed BCG-PSN, have traditionally been used as immunomodulators in the treatment of dermatitis and allergic diseases. While the sales of injectable BCG-PSN have shown steady growth in recent years, no reports of using BCG-PSN powder or its immunotherapeutic effects exist. Here, BCG-PSN powder was applied directly to the skin to evaluate the immunotherapeutic effects on mice infected with Mycobacterium tuberculosis (MTB). In total, 34 μg of BCG-PSN powder could be loaded into a microneedle patch (MNP). Mice receiving BCG-PSN powder delivered via MNP exhibited significantly increased IFN-γ and TNF-α production in peripheral blood CD4 + T cells and improved pathological changes in their lungs and spleens compared to control group mice. The immunotherapeutic effect of BCG-PSN powder delivered via MNP was better than that delivered via intramuscular injection to some extent. Furthermore, MNPs eliminate the side effects of syringes, and this study demonstrated that BCG-PSN can be clinically administrated in powder form.

Analysis of immunogenicity of tuberculosis fusion protein consisting of Ag85B, Mpt64 and HspX antigens expressed in replication and dormancy bacilli

Objective To construct protective immunity to Mycobncterium tuberculosis latent infection, a novel fusion protein consisting of HspX, the 190 to 198 peptide of Mpt64 and Ag85B, which were confirmed to be the effective protective antigens mainly expressed in the dormancy and exponential phase of growth, was constructed and its immunogenicity was investigated. Methods Ag85B and Mpt64190-198-HspX sequences were amplified by PCR and cloned into plasmids pET-28a. The fusion protein, Ag85BMpt64190-198-HspX (AMH) was expressed in E. coli BL21 and purified with Ni-NTA resins. C57BL/6 mice were immunized three times at 2-week intervals subcutaneously with AMH formulated with the adjuvant composed of dimethyl-dioctyldecyl ammonium bromide (DDA) and BCG polysaccharide nucleic acid (BCGPSN). Humoral and cell-mediated immunity responses were analyzed at five weeks after the last injection. Results AMH was expressed stably in E. coli and could be purified well by Ni-NTA affinity chromatography. C57BL/6 mice immunized with AMH subunit vaccine generated specific cellular and humoral immunologic response to the stimulation of Ag85B, Mpt64190-198 and HspX. Conclusion It suggested that AMH was a promising candidate antigen of tuberculosis subunit vaccine. Key words: Mycobacterium tuberculosis; Subunit vaccine; Fusion protein; Ag85B; HspX

Discussion on efficacy of different treatment regimen of BCG-polysaccharide nucleic acid in chronic urticaria

Objective To explore the clinical effects of different treatment regimen of BCG-polysaccharide nucleic acid (BCG-PSN) in chronic urticaria and to optimize medication.Methods According to random number table,120 patients were divided into control group,treatment group A and treatment group B,40 patients in each group.Patients in control group were treated only with desloratadine tablets,5 mg once daily orally.Based on control group,patients in both treatment groups were treated with BCG-PSN by intramuscular injection at a dose of 2 ml each time for 30 consecutive days,treatment group A once every other day and treatment group B once every 3 days.We observed efficacy on the 10th,20th and 30th day,therapy cost and adverse reaction were recorded.Results Effective rates of both treatment groups were higher than those of control group after 10 days of treatment.Effective rates on day 20 and 30 of treatment group A were 82.50％ and 90.00％ respectively,and those of control group were 57.50％ and 67.50％ respectively,there were significant differences between the two groups (P ＜ 0.05).And those of treatment group B were 80.00％ and 87.50％ respectively,compared with control group,there were statistical significant differences (P ＜ 0.05).Effective rates showed no significant differences between treatment group A and B (P ＞ 0.05).Average therapy cost of treatment group B was markedly less than that of treatment group A,there was statistical significant difference (P ＜ 0.05).Conclusion BCG-PSN has comparable efficacy used in chronic urticaria in different regimens,but the best treatment regimen is once every 3 days by intramuscular injection. Key words: BCG-polysaccharide nucleic acid (BCG-PSN); Desloratadine tablets; Chronic urticaria; Treatment regimen

A clinical study on hepatitisi B vaccine triple-therapy in chronic hepatitis B virus infection

Event Abstract Back to Event A clinical study on hepatitisi B vaccine triple-therapy in chronic hepatitis B virus infection Bang-FU Wu1, 2* and Jiang-Ying Yang2 1 Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, China 2 Guangzhou Pubang Bio-Immunological Tech Research Institute, China Aims: To observe the clinical efficacy of the admixture of hepatitis B vaccine, rhGM-CSF and BCG polysaccharide ucleic acid(for short: hepatitis B vaccine triple-therapy) combined with adefovir dipivoxil in the patients of chronic hepatitis B virus(HBV) infection. Methods: 18 HBeAg positive chronic hepatitis B(CHB) patients, 11 HBeAg positive chronic HBV carriers, 5 HBeAg negative CHB patients, 2 HBeAg negative chronic HBV carriers and 12 inactive HBsAg carriers were recruited in the study. Hepatitis B vaccine containing 20µg HBsAg, rhGM-CSF 100µg and BCG polysaccharide nucleic acid 2ml were mixed. And then the admixture injected hypodermically to the patient once every two weeks for 12 practices applications totally. Adefovir dipivoxil was taken 10mg daily for 33 patients those HBVDNA>10000 copy/ml. Quantitative HBVM(TRFIA) and HBVDNA were evaluated at week 0, 12, and 24. Results: At week 12 and 24, HBeAg seroconversion rate were 13.79%(4/29) and 27.59%(8/29) respectively, HBVDNA negative conversion rate were 37.14%(13/35), and 60.00%(21/35), HBsAg negative conversion rate were 2.08%(1/48) and 6.25%(3/48), HBsAb positive conversion rate were 16.67%(8/48) and 37.50%(18/48), HBsAg seroconversion rate were 2.08%(1/48) and 6.25%(3/48). The rate of adverse effect was 50.17%. The adverse effect include fever, headache, ache all over, bellyache, urticaria and hives, dyspnea, and tumefaction ache in the injection site after injected the admixture. Conclusions: The hepatitis B vaccine triple-therapy in combination with adefovir dipivoxil can be considered as a efficient approach for patients of chronic HBV infection, which may effectively inhibit the viral replication, improve the production of HBsAb and HBeAb, and increase HBeAg seroconversion rate. Keywords: Hepatitis B virus (HBV), Chronic hepatitis B (CHB), Hepatitis B vaccine, Chronic HBV carriers, rhGM-CSF Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Translational immunology and immune intervention Citation: Wu B and Yang J (2013). A clinical study on hepatitisi B vaccine triple-therapy in chronic hepatitis B virus infection. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00895 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 20 Jun 2013; Published Online: 22 Aug 2013. * Correspondence: Prof. Bang-FU Wu, Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, Dongguan, Guangdong, 523952, China, bangfu.wu@163.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Bang-FU Wu Jiang-Ying Yang Google Bang-FU Wu Jiang-Ying Yang Google Scholar Bang-FU Wu Jiang-Ying Yang PubMed Bang-FU Wu Jiang-Ying Yang Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.

Effect of bacille calmette-guerin polysaccharide nucleic acid (BCG-PSN) on the expression of T cell-derived cytokines in patients with atopic dermatitis

Objective To assess the changes in frequency of peripheral T lymphocytes expressing different cytokines in patients with atopic dermatitis (AD) before and after treatment with BCG-PSN and their relationship with disease severity. Methods A randomized, double blinded and placebo cross-over control study was conducted. A total of 8 patients with AD were recruited in this study. Intramuscular BCG-PSN or placebo was given to patients every other day for 36 days. Flow cytometry was performed to measure the frequency of IL4-, IL5-, IFN-γ- and TNFα-expressing peripheral CD4+ T cells and CD8+ T cells before and after the therapy. Disease severity was evaluated by atopic dermatitis area and severity index score (ADASIS). Results The difference value in IFN-γ+CD8+ T cell frequency before and after therapy was significantly higher in patients treated with BCG-PSN than in those with placebo (8.056 ± 13.962 vs -6.549 ± 10.491, U = 2.26, P 0.05). The decrease in ADASIS was 1.56 ± 1.49 in patients treated with BCG-PSN, which was statistically higher than that in placebo-treated patients (-0.05 ± 1.54, U = 2.00, P< 0.05). Conclusion As an immunomodulator, BCG-PSN may control AD by restoring the balance of T-cell subsets. Key words: Dermatitis, atopic; BCG-polysaccharide nucleic acid; Cytokines

Fusion protein Ag85B-MPT64 190–198-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice

Tuberculosis (TB) remains a major infectious disease worldwide despite chemotherapy and BCG vaccine. The efficacy of the current TB vaccine BCG varies from 0 to 80%. New vaccines that have better protection than BCG or have the capability to boost BCG-primed immunity are urgently needed. We have previously constructed a fusion protein Ag85B-MPT64 190–198-Mtb8.4 (AMM). In this study, we investigated the immunogenicity of the fusion protein AMM in a novel adjuvant of dimethyl-dioctyldecyl ammonium bromide and BCG polysaccharide nucleic acid (DDA–BCG PSN), and its capacity to boost BCG-primed immunity. The anti-Ag85B antibodies IgG1 and IgG2a were determined using ELISA and the number of spleen cells secreting IFN-γ was determined by ELISPOT. In addition, the ability of the subunit vaccine AMM to boost BCG-primed immunity against Mycobacterium tuberculosis was analyzed. The fusion protein AMM induced more effective humoral and cell-mediated immune responses in mice than Ag85B alone. Mice primed with BCG vaccination followed by boosting with AMM produced a stronger immune response and afforded a better protection against M. tuberculosis infection than mice immunized with BCG alone or BCG priming followed by boosting with Ag85B. These findings suggest that AMM is a promising candidate subunit vaccine to enhance the protective efficiency of BCG.

OL-061 A subunit vaccine consisting of fusion protein Ag85B-MPT64190-198-Mtb8.4 and adjuvant of dimethyl-dioctyldecyl ammonium and BCG polysaccharide nucleic acid enhances BCG-primed protection against Mycobacterium tuberculosis infection in mice

OL-061 A subunit vaccine consisting of fusion protein Ag85B-MPT64190-198-Mtb8.4 and adjuvant of dimethyl-dioctyldecyl ammonium and BCG polysaccharide nucleic acid enhances BCG-primed protection against Mycobacterium tuberculosis infection in mice

Clinical observation of influence of acupoint injection of BCG polysaccharide nucleic acid in summer on immune functions in 32 cases of bronchial asthma

In the treatment of 32 cases of bronchial asthma by injection of BCG polysaccharide nucleic acid (PSN) into Zusanli (ST 36), Dingchuan (Ex-B 1) and Feishu (BL 13) in summer, the total effective rate reached 84.4%, with T cell subgroup determined before and after the treatments at the same time. In summer, injection of PSN can enhance CD8+ (P<0.02) for the patients in lower level, and reduce the enlarged ratio of CD4+/CD8+ (P<0.01), indicating this method can regulate the immune functions and provides a convenient and effective method to the treatment of bronchial asthma.